IN THE SPOTLIGHT

Case Report: Abscopal effect and long-term survival in a PD-L1 negative NSCLC patient treated with radiotherapy and immuno-chemotherapy

Case Report: Abscopal effect and long-term survival in a PD-L1 negative NSCLC patient treated with radiotherapy and immuno-chemotherapy

Comprehensive evaluation of risk factors for LNM and distant metastasis in patients with NSCLC

Comprehensive evaluation of risk factors for LNM and distant metastasis in patients with NSCLC

文献速递丨ADC治疗HER2突变晚期NSCLC,DESTINY-Lung02研究数据更新_腾讯新闻

文献速递丨ADC治疗HER2突变晚期NSCLC,DESTINY-Lung02研究数据更新_腾讯新闻

Multidisciplinary Collaboration Gives Forward Momentum to HER2 IHC Testing in NSCLC: With Ronan J. Kelly, MD, MBA, FASCO; and Michelle Shiller, DO, AP/CP, MGP

Multidisciplinary Collaboration Gives Forward Momentum to HER2 IHC Testing in NSCLC: With Ronan J. Kelly, MD, MBA, FASCO; and Michelle Shiller, DO, AP/CP, MGP

Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC

Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC

Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC

Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC

No Mediastinal Lymph Node Dissection Needed in Selected Early NSCLC, Trial Says

No Mediastinal Lymph Node Dissection Needed in Selected Early NSCLC, Trial Says

David Heredia Highlighted New Research on Membrane Targets in RET+ NSCLC

David Heredia Highlighted New Research on Membrane Targets in RET+ NSCLC

高选择性小分子 TKI 宗艾替尼开启 HER2 突变 NSCLC 靶向治疗新篇章

高选择性小分子 TKI 宗艾替尼开启 HER2 突变 NSCLC 靶向治疗新篇章

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment